AZ, Daiichi Sankyo’s Enhertu scores approval in the UK
16th February 2021
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu has scored a conditional marketing authorisation in the UK for certain breast cancer patients.
The conditional marketing authorisation covers the use of Enhertu (trastuzumab deruxtecan) as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer, who have received two or more prior anti-HER2 based regimens.
The UK authorisation is based on results from the Phase II DESTINY-Breast01 trial, in which patients treated with Enhertu demonstrated a confirmed objective response rate (ORR) of 61.4%, as well as a 6.5% complete response rate and a 54.9% partial response rate.
AZ/Oxford University s COVID-19 vaccine to be evaluated in children and young adults pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Scientific breakthroughs, approvals: Latest CAR T-cell therapy related developments From new research offering promise for children s cancer to FDA registrations, we track the progress made in the past few weeks in terms of advancing CAR T-cell therapy in a number of markets.
Novartis on Friday [February 12] reported that it had received approval from Australian regulatory agency, Therapeutic Goods Administration (TGA), for Cell Therapies to manufacture and supply its CAR-T therapies commercially for eligible patients in that market.
The Cell Therapies manufacturing facility in the Peter MacCallum Cancer Center in Melbourne is now the first and only approved commercial manufacturing site for CAR T-cell therapies in Australia.
US Representative Glenn Grothman (R-WI) has introduced a House Resolution to recognize the significant role vitamin D may play in the fight against COVID-19.
Citing an article on NutraIngredients, a press release from Grothman’s office noted that in December, 120 international health, science and medical experts sent an open letter to world governments stating that there is clear evidence that vitamin D reduces COVID-19 infections, hospitalizations, and deaths.
Grothman, who is serving his fourth term representing Wisconsin’s 6th Congressional District, also pointed to a host of studies from Northwestern University, University of Chicago, and Trinity College in Dublin, Ireland, that reported strong correlations between vitamin D deficiencies and negative COVID-19 patient outcomes, including severe symptoms, hospital stays, ICU admittance, and overall mortality rate.
Last modified on Mon 15 Feb 2021 07.17 EST
The dilemmas are achingly familiar by now. Should we lock down or stay open? If we lock down, when and in what order should the different sectors of the economy open up? What about schools? Places of worship? Cultural and sporting venues?
In each case, the question being asked is essentially the same: is saving
x lives from Covid-19 worth
y potential damage to society? The question is usually framed in terms of damage to the economy rather than damage to society, because the former is easier to measure (how do you measure the damage done to religious people of not being able to pray together, to schoolchildren of not being able to mix, or to any of us of being deprived of art?) That calculation is complex enough, but feeding into it is another that’s even more morally fraught: are some human lives more valuable than others?